Palleon Pharmaceuticals
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
266 Second Ave, Waltham, Massachusetts, ...Phone Number
(857) 285-5900Website
www.palleonpharma.comRevenue
$20 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Palleon Pharmaceuticals
Palleon Pharmaceuticals functions as a biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. The company was established in 2015 and is headquartered out of Waltham, MA.Explore more
Palleon Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Palleon Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Palleon Pharmaceuticals is spiking on competitors!
Click to see if Palleon Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Palleon Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Palleon Pharmaceuticals
Palleon Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Palleon Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Palleon Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Palleon Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Palleon Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Palleon Pharmaceuticals
Compare insights from companies similar to Palleon Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Palleon Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Palleon Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Palleon Pharmaceuticals.
Palleon Pharmaceuticals financials insights
Gather financial insights about Palleon Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$47.6M
2020
Series B
$100M
Palleon Pharmaceuticals Tech Stack
A closer look at the technologies used by Palleon Pharmaceuticals
See more technologies
Most Recent Scoops
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
Event
Events
Award
Award, Engineering, Product Development, Research & Development
Facilities Relocation / Expansion
Palleon Pharmaceuticals News & Media
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
WALTHAM, Mass. & SHANGHAI--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic, E-602, in combination with Henlius’ self-developed HANLIKANG (rituximab) in patients with autoimmune diseases, including lupus nephritis (LN). DPalleon Pharmaceuticals Presents Results from the Phase 1/2 GLIMMER-01 Trial of E-602 in Combination with Cemiplimab in Patients with Solid Tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced results from the Phase 1/2 GLIMMER-01 trial of E-602, its first-in-class human sialidase enzyme therapeutic, in combination with PD-1 inhibitor cemiplimab (Libtayo®) in patients with PD-(L)1-resistant solid tumors. The results will be shared in both rapid oral and poster presentations on Saturday, November 9 at tPalleon to Present New Findings on Colorectal Tumor Microenvironment Identified with its HYDRA Platform at Society for Immunotherapy of Cancer (SITC) Annual Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present new findings from a study leveraging its HYDRA platform that suggests a link between stromal hypersialylation and immunosuppression activity within the colorectal tumor microenvironment at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place in San Diego from NovemberPalleon Pharmaceuticals Recognized as a Fierce Biotech “Fierce 15” Company for 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Palleon named as one of Fierce Biotech's “Fierce 15", which features the most innovative and promising biotech companies in the industry each year.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Palleon Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Palleon Pharmaceuticals functions as a biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. The company was established in 2015 and is headquartered out of Waltham, MA.... Read More
